Table 4.

Comparison with previously published literature

Published studies	ORR	Median PFS	Median OS
Pagano et al. [14]	55% (median DOR = 16.4 months)	–	12.6 months (range, 0.5–75.8), with a survival at 5 years was 9.3%
Musto et al. [15]	60.8% (post 4 cycles)	52.1% (15 months)	65.2% (15 months)
Musto et al. [16]	92%	8 months	12 months
D Arena et al. [17]	79%	–	55% (2 years)
Colovic et al. [18]	7/30 patients achieved remission	–	4.5 months
García-Sanz et al. [19]	37% (ORR = 29% + PR = 8%)	–	8 months
Mahindra et al. [20]
Autologous SCT	76% (at transplant)	34% at 3 years	64% at 3 years
Allogeneic SCT	64% (at transplant)	20% at 3 years	39% at 3 years
Drake et al. [21] Autologous SCT	41.2% (at day 100 post SCT)	–	25.7 (19.5–31.9 months)
Pagano et al. [14] SCT	–	HR for relapse 0.13, (95% CI 0.04–0.41)	38.1 months (range 4.8–75.8 months)
Our study Median follow up-22 months	70% (post induction chemotherapy)	11 months (95% C.I. 6.3–15.6)	21 months (95% C.I. 1–49.8)